Mounjaro (autoinjector), Mounjaro(tirzepatide)
Mounjaro, Zepbound (tirzepatide) is a protein pharmaceutical. Tirzepatide was first approved as Mounjaro (autoinjector) on 2022-05-13. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. It is known to target glucagon-like peptide 1 receptor and gastric inhibitory polypeptide receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Mounjaro, Zepbound
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tirzepatide
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TIRZEPATIDE, MOUNJARO, ELI LILLY AND CO | |||
| 2027-05-13 | NCE | ||
TIRZEPATIDE, MOUNJARO (AUTOINJECTOR), ELI LILLY AND CO | |||
| 2027-05-13 | NCE | ||
TIRZEPATIDE, ZEPBOUND, ELI LILLY AND CO | |||
| 2027-05-13 | NCE | ||
| 2026-11-08 | NP | ||
HCPCS
No data
Clinical
Clinical Trials
157 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 13 | 23 | 23 | 12 | 12 | 80 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 9 | 10 | 17 | 7 | 6 | 47 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 11 | 11 | 20 | 5 | 3 | 47 |
| Overweight | D050177 | — | E66.3 | 7 | 13 | 15 | 4 | 3 | 42 |
| Weight loss | D015431 | — | — | 3 | 4 | 2 | 1 | 3 | 13 |
| Body weight | D001835 | EFO_0004338 | — | — | 1 | 2 | 1 | 2 | 6 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | — | 1 | — | 3 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | 2 | — | 1 | — | 3 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | 2 | 1 | — | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 2 | 1 | — | 3 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 2 | 3 | — | — | 6 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | 3 | 4 |
| Weight gain | D015430 | — | — | — | 1 | 1 | — | 1 | 3 |
| Glucose metabolism disorders | D044882 | — | — | — | — | 2 | — | — | 2 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | 2 | — | — | 2 |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | 1 | — | — | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | 1 | — | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | 1 | — | — | 1 |
| Apnea | D001049 | — | R06.81 | — | — | 1 | — | — | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | 1 | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | 1 | 3 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | — | — | — | 2 |
| Body-weight trajectory | D000077962 | — | — | — | 1 | — | — | 1 | 2 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 2 | — | — | — | 2 |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | 2 | — | — | — | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | 2 | — | — | — | 2 |
| Wolfram syndrome | D014929 | Orphanet_3463 | E13.8 | — | 1 | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
| Alcoholic fatty liver | D005235 | — | K70.0 | 1 | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
| Hypoglycemia | D007003 | — | E16.2 | 1 | — | — | — | — | 1 |
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | — | — | — | 1 | 1 |
| Hidradenitis | D016575 | — | — | — | — | — | — | 1 | 1 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
| Ablation techniques | D055011 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tirzepatide |
| INN | tirzepatide |
| Description | Tirzepatide, sold under the brand name Mounjaro among others, is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Tirzepatide is administered via subcutaneous injections (under the skin).
|
| Classification | Protein |
| Drug class | peptides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2023788-19-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297839 |
| ChEBI ID | — |
| PubChem CID | 156588324 |
| DrugBank | DB15171 |
| UNII ID | OYN3CCI6QE (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,863 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mounjaro, Zepbound
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
68,838 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use